112 related articles for article (PubMed ID: 16574165)
21. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II.
Kawiak A; Piosik J; Stasilojc G; Gwizdek-Wisniewska A; Marczak L; Stobiecki M; Bigda J; Lojkowska E
Toxicol Appl Pharmacol; 2007 Sep; 223(3):267-76. PubMed ID: 17618663
[TBL] [Abstract][Full Text] [Related]
22. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
23. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy.
Puig PE; Guilly MN; Bouchot A; Droin N; Cathelin D; Bouyer F; Favier L; Ghiringhelli F; Kroemer G; Solary E; Martin F; Chauffert B
Cell Biol Int; 2008 Sep; 32(9):1031-43. PubMed ID: 18550395
[TBL] [Abstract][Full Text] [Related]
24. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
25. The high rate of endoreduplication in the repair deficient CHO mutant EM9 parallels a reduced level of methylated deoxycytidine in DNA.
Mateos S; Domínguez I; Cantero G; Pastor N; Campanella C; Cortés F
Mutat Res; 2008 Sep; 644(1-2):24-30. PubMed ID: 18640132
[TBL] [Abstract][Full Text] [Related]
26. Chromosome aberrations in Chinese hamster and human cells: a comparison using compounds with various genotoxicity profiles.
Hilliard C; Hill R; Armstrong M; Fleckenstein C; Crowley J; Freeland E; Duffy D; Galloway SM
Mutat Res; 2007 Mar; 616(1-2):103-18. PubMed ID: 17174355
[TBL] [Abstract][Full Text] [Related]
27. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
28. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.
Barret JM; Kruczynski A; Vispé S; Annereau JP; Brel V; Guminski Y; Delcros JG; Lansiaux A; Guilbaud N; Imbert T; Bailly C
Cancer Res; 2008 Dec; 68(23):9845-53. PubMed ID: 19047165
[TBL] [Abstract][Full Text] [Related]
29. Function of topoisomerase II and the consequences of inhibition.
Davies SM
Med Pediatr Oncol Suppl; 1996; 1():12-9. PubMed ID: 8643041
[No Abstract] [Full Text] [Related]
30. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin.
Olaharski AJ; Mondrala ST; Eastmond DA
Mutat Res; 2005 Apr; 582(1-2):79-86. PubMed ID: 15781213
[TBL] [Abstract][Full Text] [Related]
31. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
32. Genotoxicity and endoreduplication inducing activity of the food flavouring eugenol.
Maralhas A; Monteiro A; Martins C; Kranendonk M; Laires A; Rueff J; Rodrigues AS
Mutagenesis; 2006 May; 21(3):199-204. PubMed ID: 16595588
[TBL] [Abstract][Full Text] [Related]
33. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.
Meng LH; Ding J
Acta Pharmacol Sin; 2007 Sep; 28(9):1460-5. PubMed ID: 17723179
[TBL] [Abstract][Full Text] [Related]
34. Increased levels of DNA topoisomerases in cultured CHO cells treated with the antitumour drug 5-azacytidine.
Piñero J; López-Baena M; Ortiz T; Mateos S; Cortés F
Cytobios; 1999; 97(385):103-15. PubMed ID: 10418121
[TBL] [Abstract][Full Text] [Related]
35. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
36. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Wang SJ; Peyrollier K; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
[TBL] [Abstract][Full Text] [Related]
37. Cells lacking DNA topoisomerase II beta are resistant to genistein.
López-Lazaro M; Willmore E; Austin CA
J Nat Prod; 2007 May; 70(5):763-7. PubMed ID: 17411092
[TBL] [Abstract][Full Text] [Related]
38. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of DNA damage in vivo induced by combined application of cisplatin and sevoflurane.
Brozovic G; Orsolic N; Knezevic F; Horvat Knezevic A; Benkovic V; Vrdoljak DV; Saric A
Eur J Anaesthesiol; 2008 Aug; 25(8):642-7. PubMed ID: 18400143
[TBL] [Abstract][Full Text] [Related]
40. Effects of resveratrol on topoisomerase II-α activity: induction of micronuclei and inhibition of chromosome segregation in CHO-K1 cells.
Basso E; Fiore M; Leone S; Degrassi F; Cozzi R
Mutagenesis; 2013 May; 28(3):243-8. PubMed ID: 23462849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
